A Study of Praliciguat in Participants With Focal Segmental Glomerulosclerosis (FSGS)
Trial details
- Registry ID
- NCT07268638
- Phase
- Phase 2
Drug identity checked against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Study of Praliciguat in Participants With Focal Segmental Glomerulosclerosis (FSGS)NCT07268638 | Akebia Therapeutics | Phase 2 | Recruiting | 2027-06Estimated |
| No regulatory events match this view.This does not mean no FDA events have occurred. |